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The aLb2 integrin (leukocyte function-associated anti-
gen-1 [LFA-1]) is regulated to engage and maintain T
cell adhesion. Conformational changes in the receptor
are associated with changes in receptor-ligand affinity
and are necessary for firm adhesion. Less well under-
stood is the relationship between receptor confor-
mation and the regulation of its lateral mobility. We
have used fluorescence photobleaching recovery and
single-particle tracking to measure the lateral mobil-
ity of specific conformations of LFA-1. These mea-
surements show that different receptor conformations
have distinct diffusion profiles and that these profiles
vary according to the activation state of the cell. Nota-
bly, a high-affinity conformation of LFA-1 is mobile on
resting cells but immobile on phorbol-12-myristate-13-
acetate-activated cells. This activation-induced immo-
bilization is prevented by a calpain inhibitor and by an
allosteric LFA-1 inhibitor. Our results suggest that cur-
rent models of LFA-1 regulation are incomplete and
that LFA-1 confinement by cytoskeletal attachment
regulates cell adhesion both negatively and positively.
Introduction
The adhesion of T cells to their cellular partners is a
tightly regulated and dynamic process. At various times,
the T cell must adhere firmly to endothelial cells within
the vasculature and to antigen-presenting cells in the
lymph nodes and periphery. For each of these interac-
tions, the primary adhesion molecule pair consists of
T cell aLb2 integrin (CD11a-CD18), known as leukocyte
function-associated antigen-1 (LFA-1), and its ligand
intercellular adhesion molecule-1 (ICAM-1).
A central question regarding the function of LFA-1 has
been the relative importance of changes in receptor
affinity versus receptor clustering upon cell activation
(Carman and Springer, 2003; van Kooyk and Figdor,
2000). Changes in receptor conformation are known to
be responsible for changes in receptor affinity (Shi-
maoka et al., 2003). Although the high-affinity forms
of the integrin are necessary for adhesion (Lu et al.,
*Correspondence: dgolan@hms.harvard.edu2001b), both receptor and ligand must become engaged
and aligned at the site of adhesion under physiological
conditions (Dustin et al., 1997). Therefore, changes in
LFA-1 lateral distribution must also be important for ad-
hesion. Under certain conditions, artificially increased
LFA-1 mobility can enhance adhesion (Kucik et al.,
1996). In addition, LFA-1 has been shown to cluster after
engagement of multivalent ligand (Kim et al., 2004).
The lateral mobility of membrane receptors, including
integrins, is often regulated by interactions with cytos-
keletally associated components (Liu et al., 2000). The
mobility of the b2 integrin has been shown to depend
on both cytoskeletally associated proteins and the acti-
vation state of the cell (Geiger et al., 2000; Smith et al.,
2005; Tadokoro et al., 2003; van Kooyk and Figdor,
2000). Studies of b2 integrin mobility on resting cells
have found that the receptor is confined by cytoskeletal
attachment through the cytoplasmic tail of the receptor
(Jin and Li, 2002). Activation of the cell by phorbol-
12-myristate-13-acetate (PMA) or cytokine results in
increased receptor lateral mobility (Constantin et al.,
2000; Jin and Li, 2002; Kucik et al., 1996). These obser-
vations have supported the current paradigm of LFA-1
mobility regulation: the inactive receptor is maintained
in a confined pool and then released when it is needed
to mediate adhesion. Arguing against this simple model
is the observation that ICAM-1-ligated LFA-1 is also
confined by cytoskeletal attachment (Peters et al.,
1999). Furthermore, related integrins become confined
upon ligand binding (Felsenfeld et al., 1996).
The relationship between LFA-1 conformation and cy-
toskeletal attachment has not been explored in depth.
Advances in the characterization of monoclonal anti-
bodies (mAb) directed against specific conformations
of LFA-1 allow direct investigation of the role of integrin
conformation in receptor mobility, confinement, and ad-
hesion. Many well-characterized epitopes for both inac-
tive and active conformations have been identified, and
antibodies have been used to observe conformational
switching both in vitro and in vivo (Lu et al., 2001a; Ma
et al., 2002; Shamri et al., 2005). Recent work has estab-
lished that cell stimulation leads to a switch from the
closed to the extended form of LFA-1 and that subse-
quent interaction with ligand results in additional confor-
mational changes that mediate firm adhesion under
shear (Shamri et al., 2005). Smith et al. have observed
that cells treated with a mAb that stabilizes the high-
affinity LFA-1 conformation have a decreased mobile
fraction, although these receptors diffuse too slowly
for their diffusion coefficient to be characterized by fluo-
rescence photobleaching recovery (FPR) (Smith et al.,
2005).
We sought to understand in detail the relationship be-
tween the conformational state of LFA-1 and the regula-
tion of LFA-1 mobility. We measured the diffusion pro-
files of LFA-1 on live T cells via single-particle tracking
(SPT), a technique with greater sensitivity than FPR for
slowly diffusing receptors. We confirmed that different
conformational states of LFA-1 manifest dramatic dif-
ferences in lateral mobility. We showed that each
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298Figure 1. Lateral Mobility of LFA-1 Deter-
mined by FPR
The lateral mobility of LFA-1 was measured
by FPR. Jurkat cells were labeled with FITC-
derivatized anti-LFA-1 F(ab)’ fragments
under the following conditions: TS1/18 on
resting (control) cells (n = 13 cells), TS1/18
on PMA-treated cells (n = 22), and HI111 on
resting cells (n = 13). Resting cells were also
labeled with a fluorescent lipid, NBD-PE, to
determine the mobility of lipids in the plasma
membrane (n = 23). Each point represents the
results of at least two independent experi-
ments. Error is shown as the standard error
of the mean (SEM). (*p < 0.01, relative to
TS1/18 on resting cells; yp < 0.005, relative
to NBD-PE on resting cells.)conformational state consists of multiple subpopula-
tions with different rates of mobility and degrees of cyto-
skeletal attachment. The diffusion profiles of each con-
formational epitope also showed specific changes
upon activation of the cell by PMA. Finally, we observed
that the ligated form of LFA-1 has a unique diffusion pro-
file, establishing the ability of the cell to recognize and
respond to ligand-induced conformational changes. We
propose that conformational changes in LFA-1 are
coupled to receptor mobility, and thereby to receptor
clustering, via cytoskeletal regulators.
Results
Activation of T Cells with PMA Induces Increased
LFA-1 Mobility Measured by FPR
We used fluorescence photobleaching recovery (FPR)
to characterize the average lateral mobility of two differ-
ent LFA-1 epitopes on T cells (Figure 1). FITC-labeled
F(ab)’ fragments were used to eliminate potential cross-
linking artifacts from bivalent IgG. The TS1/18 epitope is
found on the I-like domain of the b2 chain, and the anti-
body blocks adhesion but is not conformationally spe-
cific (Beals et al., 2001; Lu et al., 2001a). The HI111 epi-
tope is found on the I-domain of the aL chain; the
antibody does not block adhesion, is specific for the
closed conformation of the integrin, and is masked by
activation (Ma et al., 2002). The lateral diffusion coeffi-
cients of these two epitopes on resting T cells were
4.66 0.93 10210 cm2s21 and 76 23 10210 cm2s21, re-
spectively. Both epitopes had large immobile fractions;
fractional mobilities were 29%6 5% and 44%6 7%, re-
spectively. Activation of cells with PMA increased the
diffusion coefficient of TS1/18 to 14 6 3 3 10210
cm2s21 (p < 0.01), but there was no significant change
in fractional mobility (35% 6 5%). We used the lateral
mobility of a fluorescently labeled lipid, nitrobenzoxa-
diazole-phosphatidylethanolamine (NBD-PE), to define
the upper limit of receptor mobility in the T cell mem-
brane. NBD-PE had a diffusion coefficient of 12 6 2 3
10210 cm2s21 and fractional mobility of 68% 6 4% in
this system. The fractional mobility of NBD-PE was sig-
nificantly greater than that of LFA-1 in both resting and
PMA-stimulated cells (p < 0.05).These FPR measurements suggested that, as re-
ported by others (Kim et al., 2004; Kucik et al., 1996),
cell activation leads to increased diffusivity of the mobile
fraction of LFA-1 molecules. Activation of the cell did not
result in a significant change in the fractional mobility of
LFA-1, suggesting that the majority of LFA-1 molecules
are in a confined state both before and after cell activa-
tion. In addition, the fractional mobility of an LFA-1 con-
formation-dependent epitope, HI111, was significantly
different from that of the conformationally nonspecific
epitope TS1/18 (p < 0.01). In order to probe with finer
resolution the relationship between LFA-1 conformation
and lateral mobility, we turned to nonensemble tech-
niques for quantifying the lateral mobility of LFA-1.
SPT of LFA-1 Epitope TS1/18 Reveals PMA
Activation-Dependent Subpopulations
Single-particle tracking has been employed at 30 frames
per second (FPS) to measure the lateral mobility of LFA-
1 (epitopes IB4 and 2E6) on transformed B cells (Jin and
Li, 2002; Kucik et al., 1996). These experiments revealed
that cell activation causes a substantial increase in the
diffusivity of LFA-1, in agreement with our FPR results.
We reasoned that the increased sensitivity of SPT mea-
surements for slowly diffusing molecules could resolve
the identity of the immobile fraction of LFA-1 found in
FPR experiments on T cells. Cells were labeled with an-
tibody- or ligand-adsorbed beads, and trajectories of
individual beads attached to LFA-1 were observed with
high-speed video enhanced microscopy (Mirchev and
Golan, 2001; Saxton and Jacobson, 1997). We used
high-speed measurements over a short duration (1000
FPS over 4 s) to minimize contributions of cell motility
to the observed trajectories. Trajectories were analyzed
by fitting the mean-square displacement (MSD) curve
according to standard methods (see Supplemental
Data available with this article online) (Saxton and Ja-
cobson, 1997). The MSD data could be analyzed to yield
three parameters for each trajectory: Dmicro, the diffu-
sion coefficient over a short time interval (4 ms); Dmacro,
the time-dependent diffusion coefficient fit over a long
time interval (1.5 s); and a, a parameter that describes
the time dependence of the diffusion coefficient and
indicates the mode of motion of the labeled molecule.
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Mean Valuesa Subpopulationsb
Label Cell Treatmentc n Dmicro Dmacro a % Dmobile % Dimmobile
HI111 E6.1 untreated 70 9.0 6 0.6 2.4 6 0.4 0.7 6 0.1 64 2.2 6 0.4 36 0.15 6 0.47
HI111 E6.1 cytoD 33 11 6 0.8 4.5 6 0.7 0.9 6 0.1 82 4.1 6 0.3 18 0.42 6 0.62
TS1/18 E6.1 untreated 75 7.3 6 0.5 1.8 6 0.3 0.8 6 0.1 28 4.7 6 0.9 72 0.44 6 0.55
TS1/18 E6.1 cytoD 36 7.8 6 0.8 2.8 6 0.6 1.0 6 0.1 66 3.1 6 0.5 34 0.31 6 0.68
TS1/18 E6.1 PMA 39 8.2 6 0.9 3.5 6 0.7 0.9 6 0.1 51 5.3 6 0.9 49 0.72 6 0.87
TS1/18 E6.1 lovastatin 42 8.3 6 0.6 1.8 6 0.3 0.7 6 0.1 41 3.6 6 0.8 59 0.37 6 0.70
TS1/18 E6.1 PMA+lovastatin 42 7.3 6 0.9 2.3 6 0.4 0.8 6 0.1 61 3.0 6 1.5 39 0.11 6 1.85
TS1/18 E6.1 PMA+cal-I 46 5.2 6 0.8 1.6 6 0.3 1.0 6 0.1 39 3.0 6 0.7 61 0.27 6 0.53
TS1/18 PBL untreated 40 3.3 6 0.7 0.8 6 0.4 1.3 6 0.1 13 3.8 6 1.9 87 0.14 6 0.73
TS1/18 PBL PMA 46 5.4 6 0.6 0.6 6 0.1 1.0 6 0.1 33 1.3 6 1.0 67 0.11 6 0.71
MEM148 E6.1 untreated 39 8.2 6 0.7 2.1 6 0.4 0.7 6 0.1 46 4.0 6 1.7 54 0.32 6 1.60
MEM148 E6.1 PMA 31 5.5 6 1.1 1.4 6 0.4 1.1 6 0.1 30 4.4 6 1.0 70 0.27 6 0.67
MEM148 E6.1 lovastatin 45 8.1 6 0.6 1.0 6 0.2 0.5 6 0.1 60 1.2 6 0.7 40 0.13 6 0.90
MEM148 E6.1 PMA+lovastatin 44 4.7 6 0.7 1.6 6 0.4 0.9 6 0.1 47 2.5 6 1.0 53 0.15 6 1.00
MEM148 E6.1 PMA+cal-I 42 5.6 6 0.7 1.5 6 0.3 0.9 6 0.1 46 2.2 6 0.5 54 0.25 6 0.44
MEM148 PBL untreated 46 4.8 6 0.6 0.9 6 0.2 1.0 6 0.1 49 1.5 6 0.6 51 0.12 6 0.55
MEM148 PBL PMA 42 2.0 6 0.5 0.11 6 0.03 1.2 6 0.1 7 0.9 6 2.5 93 0.04 6 0.70
ICAM-1 E6.1 untreated 38 6.6 6 0.8 1.5 6 0.3 0.9 6 0.1 18 7.0 6 1.2 82 0.52 6 0.57
ICAM-1 E6.1 cytoD 48 8.5 6 0.6 2.7 6 0.4 0.8 6 0.1 58 3.7 6 0.4 42 0.43 6 0.46
ICAM-1 E6.1 PMA 24 3.7 6 0.8 1.3 6 0.3 0.9 6 0.1 <1 NDd 86 0.94 6 0.24
a Values represent mean 6 SEM. Units of Dmicro and Dmacro are 10
210 cm2s21.
b Population analysis of Dmacro values was used to determine the percentage of trajectories in the mobile and immobile ranges of the diffusion
profile (see text for additional detail and Figure S4 for additional analysis).
c Conditions were: untreated (buffer + 0.1% DMSO), cytoD (1 mM in buffer + 0.1% DMSO), PMA (200 ng/mL in buffer + 0.1% DMSO), lovastatin
(100 mM in buffer + 0.1% DMSO), PMA + lovastatin (200 ng/mL PMA, 100 mM lovastatin in buffer + 0.1% DMSO), PMA + cal-I (200 ng/mL PMA,
26 mM cal-I in buffer + 0.1% DMSO). Buffer was HBSSB. See Supplemental Data for additional analysis.
d See text for discussion of the immobile assignment of trajectories obtained for this condition.The mean values of each of these parameters showed
relatively small differences among the different LFA-1
epitopes on resting and activated cells (Table 1). As
described below, however, subpopulation analysis of
Dmacro values showed that LFA-1 mobility varied mark-
edly according to its molecular conformation and the
activation state of the cell. Therefore, we focused our
analysis on these subpopulations.
Analysis of LFA-1 Dmacro data showed the presence of
subpopulations for virtually all LFA-1 epitopes in resting
and activated cells (Figure 2 and see below). We used
a kernel density function to calculate a population den-
sity estimate and thereby determine the relative contri-
butions of the component populations (see Supplemen-
tal Data, Section S5) (Sheather, 2004). In general, two
subpopulations of LFA-1 trajectories could be distin-
guished by this analysis: a mobile population, with
Dmacro centered at values around 3.6 3 10
210 cm2s21;
and an immobile population, with Dmacro centered at
values around 0.3 3 10210 cm2s21 (Figure S4). We refer
to the overall population density as the LFA-1 diffusion
profile for each set of conditions.
The major population of LFA-1 labeled by mAb TS1/18
was immobile, representing 72% of the diffusion profile
at Dmacro = 0.4 6 0.6 3 10
210 cm2s21 (Figure 2B). We
used cytochalasin D (cytoD), which inhibits actin poly-
merization, to test the effect of disrupting cytoskeletal
interactions on LFA-1 diffusion. Additionally, we used
PMA to activate cells. Treatment with either cytoD or
PMA caused an increase in the mobile population of
LFA-1 (Figure 2C, 66% at Dmacro = 3.1 6 0.5 3 10
210
cm2s21; Figure 2D, 51% at Dmacro = 5.3 6 0.9 3 10
210
cm2s21). These results suggested that LFA-1 exists inat least two distinct populations on both resting and
activated cells. A large fraction of LFA-1 appears to be
maintained in the immobile state on resting cells (Fig-
ure 2E), and this reserve pool of receptors is released
from cytoskeletal constraints upon cell activation. These
observations are qualitatively consistent with previous
reports of cytoD and PMA effects on integrin mobility
and clustering, although we observed a larger mobile
population of LFA-1 on resting Jurkat cells than has
been observed on other cell types (Kim et al., 2004;
Kucik et al., 1996).
SPT of Conformation-Dependent Epitopes HI111 and
MEM148 Shows Divergent Shifts in Subpopulations
We employed two known conformation-dependent
epitopes of LFA-1, HI111 and MEM148, to determine
whether the diffusion profile of LFA-1 was dependent
on molecular conformation. HI111 labels an inactive,
closed conformation of LFA-1 (Ma et al., 2002), whereas
MEM148 labels an active, open conformation of LFA-1
(Tan et al., 2001). The MEM148 epitope is found on the
C-terminal region of the b2 chain, and the antibody nei-
ther blocks adhesion nor activates the cell (Drbal et al.,
2001; Tan et al., 2001).
Both HI111 and MEM148 showed diffusion profiles
different from those of TS1/18 (Figure 3). In resting cells,
the mobile population was large for both epitopes: for
HI111, 64% at Dmacro = 2.2 6 0.4 3 10
210 cm2s21; for
MEM148, 46% at Dmacro = 4 6 2 3 10
210 cm2s21. These
data indicated that both the inactive, closed LFA-1 con-
formation labeled by HI111 and the active, open confor-
mation labeled by MEM148 have larger mobile popula-
tions than TS1/18-labeled receptors on resting Jurkat
Immunity
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The diffusion of LFA-1 labeled with TS1/18 was observed with F(ab)’-coated beads and high-speed microscopy (see Experimental Procedures).
(A) Representative trajectories (4 s, 1000 FPS) are shown for control cells in buffer containing DMSO (0.1%), cells treated with cytoD (1 mM, 0.1%
DMSO), and cells treated with PMA (200 ng/mL, 0.1% DMSO). Representative trajectories are sorted by Dmacro and colored according to the sub-
population in which they were classified: immobile (green) or mobile (blue). All trajectories are oriented such that the origin is toward the bottom
of the figure and the terminus is toward the top of the figure. Scale bar represents 1 mm. Each condition represents the results of 2–4 independent
experiments.
(B–D) The distribution of calculated diffusion constants (Dmacro) is plotted as a histogram (gray) for each treatment: (B) control, (C) cytoD, (D) PMA.
The population density is shown in black (solid line); the best fit of the population density is shown in black (dotted line) with the best-fitted sub-
populations colored as in (A). The dominant subpopulation is indicated by a box that states the relative area of the peak. Complete peak fitting
results are given in Table S2.
(E) The calculated MSD versus time interval is shown for three representative trajectories within each subpopulation, colored as in (A).cells. In the case of HI111, treatment with cytoD caused
an increase in both the fraction of mobile trajectories
and their diffusivity (Figure 3B, 82% at Dmacro = 4.1 6
0.3 3 10210 cm2s21). This observation suggested that
the immobile fraction of receptors labeled by HI111 is
tethered by cytoskeletal regulators on resting cells.
Interestingly, the effect of PMA on the diffusion profile
of MEM148 was opposite to the effect of this cellular ac-
tivator on the diffusion profile of TS1/18 (Figure 3E). The
mobile population decreased from 46% to 30%, while
the immobile population increased to 70% at Dmacro =
0.3 6 0.7 3 10210 cm2s21. Furthermore, computation
of weighted parameters for the immobile population
showed a dramatic increase in the a value, from 0.6 6
0.2 to 1.4 6 0.1, and a decrease in the Dmicro value,
from 7 6 1 3 10210 cm2s21 to 2.3 6 0.7 3 10210 cm2s21(see Table S2). These results suggested that PMA acti-
vation causes the active, open conformation labeled
by MEM148 to become largely immobile and to experi-
ence directed motion. We also used FPR to confirm
that the vast majority of MEM148-labeled receptors
were laterally immobile on cells treated with PMA (data
not shown).
SPT Shows that ICAM-1-Ligated LFA-1 Is Immobile
on Both Resting and PMA-Activated Cells
We next considered the effects of LFA-1 binding to its
native ligand, ICAM-1. The trajectories of LFA-1-ICAM-
1 complexes on cells could be observed with the use
of ICAM-1-labeled beads (Figure 4; Peters et al., 1999).
We found that ICAM-1-ligated LFA-1 occupied primarily
the immobile region of the diffusion profile (Figure 4A,
LFA-1 Conformation Is Coupled to Lateral Mobility
301Figure 3. Single-Particle Tracking of Conformation-Dependent Epitopes HI111 and MEM148
The diffusion of LFA-1 labeled with HI111 (specific for the closed conformation of LFA-1) or MEM148 (specific for the open conformation of LFA-
1) was observed with F(ab)’-coated beads and high-speed microscopy.
(A and B) Cells labeled with HI111 beads were treated with (A) control buffer containing DMSO (0.1%) or (B) cytoD (1 mM, 0.1% DMSO).
(C) Representative trajectories are shown for control cells (top) and cytoD-treated cells (bottom).
(D and E) Cells labeled with MEM148 beads were treated with (D) control buffer containing DMSO (0.1%) or (E) PMA (200 ng/mL, 0.1% DMSO).
(F) Representative trajectories are shown for control cells (top) and PMA-treated cells (bottom). Scale bar represents 1 mm. Each condition
represents the results of 2–4 independent experiments.
Population and trajectory data are plotted as described in the legend to Figure 2. The epitope recognized by HI111 is masked upon activation
with PMA; therefore, it could not be labeled or observed on PMA-treated cells.82% at Dmacro = 0.5 6 0.6 3 10
210 cm2s21). Treatment
with cytoD caused an increase in the mobile population
(Figure 4B, 58% at Dmacro = 3.7 6 0.4 3 10
210 cm2s21),
showing that the immobile population was sensitive to
cytoskeletal disruption. On PMA-treated cells, ICAM-1-
ligated LFA-1 trajectories were centered in an intermedi-
ate region of the diffusion profile (Figure 4C, 86% at
Dmacro = 0.9 6 0.2 3 10
210 cm2s21). Therefore, assign-
ment of this population as ‘‘mobile’’ or ‘‘immobile’’ was
difficult (see Figure S4). However, the weighted Dmicro
value for this population was reduced from 14 6 1 3
10210 cm2s21 in untreated cells to 3.1 6 0.6 3
10210 cm2s21 in PMA-treated cells. Together with the
relatively low Dmacro value, the Dmicro value that was
more consistent with an immobile population (see Table
S2) suggested that this peak should be considered im-
mobile, most likely due to cytoskeletal attachment of
LFA-1 upon ICAM-1 ligation. This interpretation was
also consistent with biochemical, biophysical, and func-
tional evidence in the literature (Dustin et al., 2004;
Peters et al., 1999).
A Conformational Inhibitor Alters the Diffusion
Profile of LFA-1
Several small molecule inhibitors are known to interfere
with LFA-1-ICAM-1 interactions. Lovastatin is the arche-
typal ‘‘L-site’’ inhibitor (also called the I-domain alloste-
ric site inhibitor); this drug induces a conformational
change in the I-domain of LFA-1, preventing adoptionof the active I-domain conformation required for ligand
binding (Kallen et al., 1999; Weitz-Schmidt et al., 2004;
Welzenbach et al., 2002). We tested whether the confor-
mational change caused by this inhibitor would alter the
LFA-1 diffusion profile (Figure 5).
Compared to untreated cells (Figure 2B), lovastatin-
treated cells showed an increase in the mobile popula-
tion observed with TS1/18 (Figure 5A, 41% at Dmacro =
3.6 6 0.8 3 10210 cm2s21). Lovastatin had a similar
effect in PMA-activated cells, such that the primary
LFA-1 population was laterally mobile (Figure 5B, 61%
at Dmacro = 36 23 10
210 cm2s21; compare to Figure 2D).
Lovastatin-treated cells observed with MEM148 also
showed an increase in the mobile population (Figure 5E,
60% at Dmacro = 1.26 0.73 10
210 cm2s21) compared to
untreated cells (Figure 3D, 46% at Dmacro = 46 23 10
210
cm2s21). This mobile population was largely maintained
in PMA-activated cells treated with lovastatin (Figure 5F,
47% at Dmacro = 36 1 3 10
210 cm2s21). The latter result
suggested that lovastatin inhibits the activation-induced
conformational change in LFA-1 required to restrict the
diffusion of the mobile population (compare Figure 5F
to Figure 3E).
A Calpain Inhibitor Alters LFA-1 Mobility
Talin is a central regulator of cellular adhesion dynamics
and a putative regulator of LFA-1 (Smith et al., 2005;
Stewart et al., 1998). The regulatory function of talin is
mediated by calpain, which cleaves the talin head
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et al., 2004). We tested the involvement of calpain ac-
tivity in LFA-1 mobility regulation by examining the ef-
fect of calpain inhibitor I (cal-I) on activation-induced
changes in the lateral mobility of LFA-1 (Figure 5). We
reasoned that calpain inhibition might attenuate the
cytoskeletal release of TS1/18-labeled LFA-1 in cells
treated with PMA. Indeed, upon PMA stimulation, TS1/
18-labeled LFA-1 showed a smaller mobile population
in cal-I-treated cells (Figure 5C, 39% at Dmacro = 3.0 6
0.7 3 10210 cm2s21) than in untreated cells (Figure 2D,
51% at Dmacro = 5.3 6 0.9 3 10
210 cm2s21). We also
tested for the involvement of calpain proteolysis in the
activation-induced immobilization of MEM148-labeled
LFA-1. We found that cal-I treatment maintained the
Figure 4. Single-Particle Tracking of ICAM-1-LFA-1 Adhesion
Complex
(A–C) The diffusion of ICAM-1-LFA-1 complexes was observed by
SPT with ICAM-1-labeled beads. Cells were treated with buffer con-
taining: (A) DMSO (0.1%), (B) cytoD (1 mM, 0.1% DMSO), or (C) PMA
(200 ng/mL, 0.1% DMSO).
(D) Representative trajectories are shown for control (top), cytoD-
treated (middle), and PMA-treated (bottom) cells. Scale bar repre-
sents 1 mm. Each condition represents the results of 2–4 indepen-
dent experiments.
Population and trajectory data are plotted as described in the legend
to Figure 2.large mobile population of LFA-1 (Figure 5G, 46% at
Dmacro = 2.2 6 0.5 3 10
210 cm2s21) that was lost upon
PMA stimulation (Figure 3E, 30% at Dmacro = 4 6 1 3
10210 cm2s21). Together, these inhibition studies sup-
ported a key role for calpain activity in the PMA-stimu-
lated cytoskeletal regulation of LFA-1.
Lateral Mobility of LFA-1 Is Reduced on PBL
Compared to Jurkat, but Shows Similar
Changes upon PMA Activation
To ascertain whether our observations of LFA-1 mobility
regulation in Jurkat were specific to this transformed cell
line, we repeated our key experiments in peripheral
blood lymphocytes (PBL) (Figure 6). We used both the
TS1/18 and MEM148 labels to measure LFA-1 mobility
on resting and PMA-stimulated PBL. For both labels,
LFA-1 manifested relatively slow diffusion (Dmacro =
0.1–0.9 3 10210 cm2s21) in resting PBL compared to
Jurkat cells, but the immobile and mobile populations
were still well resolved (see Figure S4). Each label
showed the same regulation profile on PBL as on Jurkat:
TS1/18 was immobile on resting cells (Figure 6A, 87% at
Dmacro = 0.1 6 0.73 10
210 cm2s21) and was partially re-
leased upon cell activation (Figure 6B, 33% at Dmacro =
16 13 10210 cm2s21), whereas MEM148 showed a large
mobile population on resting cells (Figure 6C, 49% at
Dmacro = 1.5 6 0.6 3 10
210 cm2s21) and an absence of
mobile molecules on activated cells (Figures 6D and 6E).
Although the magnitudes of the population shifts and
diffusion coefficients were different in the two cell types,
both PBL and Jurkat responded to PMA stimulation by
releasing TS1/18-labeled LFA-1 and immobilizing
MEM148-labeled LFA-1.
Model of LFA-1 Regulation
Based on the diffusion profiles of LFA-1 populations la-
beled by HI111, MEM148, TS1/18, and ICAM-1, we pro-
pose a model of LFA-1 regulation that has at least four
conformational states (Figure 6F). The inactive (closed)
conformation labeled by HI111 is primarily mobile. The
active (open) conformation labeled by MEM148 is also
primarily mobile on resting cells, but is immobilized by
cytoskeletal attachment when the cell is activated. The
TS1/18 epitope is not conformationally specific, and its
use is intended to provide an indication of the conforma-
tional milieu of all LFA-1 receptors. However, because
both HI111 and MEM148 epitopes are primarily mobile
on resting cells, the primarily confined TS1/18 profile
must represent more than the sum of these two popula-
tions. Additionally, the contrary population shift be-
tween TS1/18 and MEM148 observed upon PMA treat-
ment supports the existence of a third (intermediate)
conformational state. The ICAM-1-ligated receptor is
primarily immobile on resting cells and becomes almost
totally immobile upon PMA treatment. This unique pro-
file likely signifies the presence of a fourth, ligand-
induced conformational state.
We speculate that the T cell could effectively control
the activity of LFA-1 by altering the equilibria among mo-
bile and cytoskeletally confined receptor pools. From
our observations, it appears that LFA-1 is regularly
found in multiple mobility states under any given set of
conditions. We propose that the system can be consid-
ered as a set of chemical equilibria involving at least four
LFA-1 Conformation Is Coupled to Lateral Mobility
303Figure 5. Single-Particle Tracking on Inhibitor-Treated Cells
The diffusion of LFA-1 labeled with TS1/18 or MEM148 was observed by SPT in the presence of lovastatin or calpain inhibitor I.
(A–C) Cells labeled with TS1/18 beads were treated with buffer containing: (A) lovastatin (100 mM, 0.1% DMSO), (B) lovastatin and PMA
(200 ng/mL), or (C) calpain inhibitor I (26 mM, 0.1% DMSO) and PMA (200 ng/mL).
(D) Representative trajectories are shown for each condition.
(E–G) Cells labeled with MEM148 beads were treated with buffer containing: (E) lovastatin (100 mM, 0.1% DMSO), (F) lovastatin and PMA
(200 ng/mL), (G) calpain inhibitor I (26 mM, 0.1% DMSO) and PMA (200 ng/mL).
(H) Representative trajectories are shown for each condition. Scale bar represents 1 mm. Each condition represents the results of 2–4 indepen-
dent experiments.
Population and trajectory data are plotted as described in the legend to Figure 2.conformational states of the receptor in mobile and
cytoskeletally attached forms. In this model, the T cell
could control LFA-1 activity by altering the mobile pop-
ulation of the relevant conformational state, and thereby
control receptor clustering. Additionally, outside-in and
inside-out signaling mechanisms could positively or
negatively regulate LFA-1 activity by altering the equilib-
ria among the various conformational states. As one ex-
ample, these complex equilibria could be regulated by
the site-specific phosphorylation of LFA-1 (Fagerholm
et al., 2005). The differences we observe between PBL
and Jurkat cells could be caused by variations in the
expression of one or more cytoskeletal regulators, re-
sulting in a perturbation of the equilibrium that alters
the cytoskeletally attached population of LFA-1.Discussion
Our results establish that each conformational state of
LFA-1 has a characteristic diffusion profile in the plasma
membrane of the T cell. In brief, it appears that cell acti-
vation mobilizes the intermediate conformation of LFA-1
in order to maximize receptor-ligand interactions, while
cytoskeletal regulators preferentially immobilize the
open and ligated conformations of LFA-1 in order to sta-
bilize adhesion. The lateral mobility of LFA-1 is similarly
regulated on Jurkat cells and peripheral blood lympho-
cytes, although the magnitudes of the population shifts
and diffusion coefficients are different between the two
cell types. Our results are consistent with a mass-action
model of LFA-1 accumulation at sites of adhesion
Immunity
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Trajectories of TS1/18- or MEM148-labeled beads were observed on resting or PMA-treated PBL.
(A and B) Cells labeled with TS1/18 beads were treated with buffer containing: (A) DMSO (0.1%) or (B) PMA (200 ng/mL, 0.1% DMSO).
(C and D) Cells labeled with MEM148 beads were treated with buffer containing: (C) DMSO (0.1%) or (D) PMA (200 ng/mL, 0.1% DMSO).
(E) Representative trajectories are shown for each condition. Scale bar represents 1 mm. Each condition represents the results of three indepen-
dent experiments.
Population and trajectory data are plotted as described in the legend to Figure 2.
(F) Based on our observations, we propose a model for the regulation of LFA-1 lateral diffusion on T cells. Top: The mAbs and ligand used in SPT
and FPR experiments label specific LFA-1 conformations: HI111 labels the closed conformation (blue), TS1/18 labels an intermediate conforma-
tion (green) in addition to the closed and open forms, MEM148 labels the open conformation (yellow), and ICAM-1 induces the ligated confor-
mation (red). Middle: The conformations of LFA-1 can be considered within a set of chemical equilibria in which receptor conformation and lateral
mobility are variable. LFA-1 confinement by cytoskeletal attachment is denoted by an asterisk. On the resting cell, the closed conformation (C) of
LFA-1 exists primarily as freely diffusing receptors. An intermediate conformation (Oi*) is primarily confined by cytoskeletal attachment, possibly
through interactions with talin. The open conformation (O) of the receptor is primarily mobile on resting cells. Bottom: Cell activation releases the
confinement of the intermediate conformation via calpain activity to produce a primarily mobile population (Oi). In contrast, receptors in the open
conformation are confined by cytoskeletal attachment (O*). In both resting and activated cells, ICAM-1-ligated LFA-1 is largely confined by
cytoskeletal attachment after ligation induces the bound conformation of the receptor (OL*).
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305(Dustin et al., 2004; Kim et al., 2004) and with the notion
that immobilization of ligated LFA-1 through cytoskele-
tal attachment may be critical in physiological settings
(Shamri et al., 2005). Importantly, our results also sug-
gest that the conformational state and lateral mobility
of LFA-1 are coupled in order to provide regulation of
receptor function on lymphocytes.
Although previous reports have examined the lateral
mobility of LFA-1 via SPT (Kucik et al., 1996; Peters
et al., 1999) and FPR (Gaborski et al., 2005; Kim et al.,
2004; Smith et al., 2005), we describe here a set of exper-
iments that characterizes directly the mobility of multi-
ple conformational epitopes of LFA-1. Under virtually
all conditions, we observe the presence of at least two
distinct populations of LFA-1: a mobile population and
an immobile population. Deconvolution of the popula-
tions according to Dmacro values reveals much more
substantial changes in LFA-1 mobility than the average
values measured for the population as a whole. There-
fore, for each set of conditions, we have analyzed the
relative proportions of the mobile and immobile popula-
tions within the diffusion profile.
Previous models of LFA-1 regulation have proposed
that the molecule is confined on resting cells and is re-
leased from its cytoskeletal constraints upon cell activa-
tion, resulting in increased mobility. Our results suggest
a more complex and subtle regulation of LFA-1 mobility,
in which the closed conformation is mobile on resting
cells and the ligated conformation is confined on acti-
vated cells. We also conclude that interactions with cy-
toskeletally attached components are responsible, at
least in part, for the slow diffusion of the immobile pop-
ulations of all LFA-1 conformations. These populations
are sensitive to treatment with cytoD and have smaller
microdiffusion coefficients than the mobile populations,
suggesting that the immobile molecules are tethered to
the cytoskeleton.
The diffusion profiles of LFA-1 show evidence of both
inside-out and outside-in signaling. Inside-out stimula-
tion of the cell by PMA causes a large increase in the mo-
bile population of LFA-1 that is labeled by TS1/18. Cell
activation also substantially alters the diffusion profiles
of the activation epitope, MEM148, and of ICAM-1-
ligated LFA-1. Outside-in signaling is suggested by the
observation that the various conformational epitopes
of LFA-1 demonstrate markedly different diffusion pro-
files on both resting and PMA-activated cells, consistent
with the propagation of conformational information from
the ectodomains of LFA-1 to cytoskeletal regulators of
the receptor.
The LFA-1 diffusion profile is modified by an allosteric
inhibitor of I-domain conformational changes. Lova-
statin is a well-characterized L-site inhibitor that binds
to LFA-1 and prevents the I-domain and I-like domain
conformational changes that are required for ICAM-1
binding (Welzenbach et al., 2002). When LFA-1 mobility
is observed by TS1/18 epitope labeling, lovastatin treat-
ment results in an increase in the mobile population on
both resting and PMA-stimulated cells. Similarly, lova-
statin increases the mobile population of the activation
epitope MEM148 on resting cells. Importantly, lovastatin
prevents the loss of the mobile population of MEM148-
labeled LFA-1 upon PMA activation. This result sug-
gests that the conformational change induced by theinhibitor mimics the open conformation labeled by
MEM148, allowing the receptor to retain its laterally mo-
bile character. Thus, effects on receptor lateral mobility
could represent a substantial component of the mech-
anism by which allosteric inhibitors regulate LFA-1
function.
We used an inhibitor of calpain activity to confirm that
calpain is one of the cytoskeletal regulators of LFA-1
(Franco et al., 2004; Stewart et al., 1998). A likely tar-
get of calpain is the cytoskeletally associated protein
talin, which is known to anchor integrins including
LFA-1 (Franco et al., 2004; Schoenwaelder et al., 1997;
Schoenwaelder and Burridge, 1999; Stewart et al.,
1998). In Jurkat cells, we found evidence that calpain
cleavage is responsible for releasing the immobile pool
of LFA-1 upon PMA stimulation. Our results also sug-
gested that calpain activity is necessary for immobilizing
the active conformation of LFA-1, implying that calpain
cleavage of a regulatory protein is upstream of the
immobilization interaction. For example, the cleavage
of talin by calpain could be necessary to allow a down-
stream cytoskeletal regulator to recognize and immobi-
lize the active conformation of LFA-1, perhaps by recog-
nition of a shared binding site.
We compared the lateral mobility of LFA-1 on Jurkat
cells to that on PBL and found that the profile of mobility
regulation was similar on the two cell types. The diffu-
sion coefficient of LFA-1 on PBL was lower than that
on Jurkat under all conditions, and the magnitude of re-
sponse to cell activation was altered. Nonetheless, the
similarity in the direction of response suggests that sim-
ilar cytoskeletal regulators are involved in the two cell
types. Our finding that the mobile fraction of LFA-1 is
larger on Jurkat cells than on PBL may help to explain
the increased adhesion manifested by transformed
LFA-1-expressing cells (Sigal et al., 2000). The specific
mechanisms responsible for these changes may be rel-
evant for neoplastic phenotypes that are associated
with altered LFA-1 regulation (Tanaka, 1999).
In summary, we have observed the diffusion of LFA-1
on live T cells by a combination of ensemble (FPR) and
nonensemble (SPT) methods. We find that conforma-
tional epitopes of the receptor have distinct diffusion
profiles that are altered by cell activation. Our observa-
tions are consistent with a mass-action model of LFA-
1 accumulation at sites of adhesion, and they provide
a mechanism for adhesion strengthening. Additionally,
we find evidence that allosteric inhibitors of LFA-1 stabi-
lize a conformation of the receptor that has high mobility
and is incapable of binding ligand (Weitz-Schmidt et al.,
2001). Together, these results provide a new dynamic
picture of LFA-1 regulation that couples receptor mobil-
ity and conformational change.
Our findings may also shed light on a continuing
debate in the literature regarding the importance of
changes in LFA-1 affinity versus clustering. Strong evi-
dence has been found for the role of both mechanisms
in LFA-1-mediated adhesion, and affinity and clustering
are generally treated as separate mechanisms. While
both mechanisms are necessary for adhesion (Kim
et al., 2004; van Kooyk and Figdor, 2000), our data sug-
gest that attempting to separate these two mechanis-
tic concepts may be unwarranted. There is little doubt
that LFA-1 conformational changes alter affinity of the
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306receptor (Shimaoka et al., 2001). By definition, changes
in receptor clustering require alterations in receptor mo-
bility (Klemm et al., 1998). Our results suggest that the
mobility of LFA-1 is controlled by recognition of its con-
formational state by cytoskeletally attached proteins. In
turn, conformational states of the receptor are regulated
by both outside-in and inside-out signaling mechanisms
(Kim et al., 2003; Porter et al., 2002). We propose that
each conformational state of the receptor experiences
a specific diffusion profile, which then controls the clus-
tering of that receptor state. In this way, receptor affinity
and mobility (Dustin et al., 1996, 2001) are both opti-
mized for interaction with the intended multivalent li-
gand (Gestwicki et al., 2002; Kiessling et al., 2006), and
receptor affinity state (conformation) and mobility (clus-
tering) are integrated through the specific recognition of
integrin conformation by cytoskeletal regulators.
Experimental Procedures
Antibodies and Reagents
Antibodies were purchased as mouse IgG and then digested and
purified as F(ab)’ fragments according to standard procedures.
TS1/18 antibody against b2 integrin (CD18) was purchased from
Pierce Biotechnology (Rockford, IL), and clone MEM-148 was pur-
chased from Serotec Ltd. (Kidlington, Oxford, UK). HI111 antibody
against aL integrin (CD11a) was purchased from BD Biosciences
(San Diego, CA). Recombinant human ICAM-1 was purchased
from R&D Systems, Inc. (Minneapolis, MN). NBD-PE was purchased
from Avanti Polar Lipids (Alabaster, AL). Cytochalasin D and PMA
were purchased from EMD Biosciences (San Diego, CA). Isotype
control mouse IgG, calpain inhibitor I, Accuspin System-Histopaque
1077, and buffer reagents were purchased from Sigma-Aldrich,
Inc. (St. Louis, MO); cell media and buffers were purchased from
Invitrogen, Inc. (Carlsbad, CA).
Cells
Jurkat cells, clone E6.1, were obtained from ATCC (Manassas, VA)
and grown in RPMI media supplemented with 10% fetal bovine se-
rum and penicillin/streptomycin (1000 U/mL). Cells were harvested
from cultures in exponential growth and washed three times with
Hank’s balanced salt solution (HBSS) supplemented with 1% (m/v)
BSA (HBSSB). The cells were then resuspended in HBSSB contain-
ing either DMSO alone (0.1% v/v) or DMSO with PMA (200 ng/mL),
cytoD (5 mg/mL), lovastatin (100 mM), or calpain inhibitor I (26 mM). Al-
iquots of the cell suspension (0.25 mL) were incubated for 30 min at
37C and labeled with polystyrene microspheres for another 15 min
at 37C. The samples were then diluted to 1 ml with HBSSB and
transferred to a 24-well plate containing 12 mm circular coverslips
treated with cell-tak (BD Pharmingen). The plate was centrifuged
at w500 RPM for 7 min and then the wells were carefully washed
seven times with fresh HBSSB (1 mL). The coverslip was then trans-
ferred to a microslide, seated with a thin circle of vacuum grease,
and sealed with Cytoseal 60 (Richard-Allan Scientific, Kalamazoo,
MI). Samples were observed experimentally within 90 min of sealing.
Peripheral blood lymphocytes (PBL) were isolated from normal
whole blood by centrifugation with Histopaque 1077. Blood ob-
tained from individual donors (2–3 mL) was centrifuged according
to the manufacturer’s protocol. Mononuclear cells at the interface
were removed and washed three times with HBSS (4 mL). Cells
were then incubated in RPMI 1640 containing 10% autologous
plasma and penicillin/streptomycin (1000 U/mL) for 24 hr. Nonadher-
ent cells were then used for experiments within 12 hr. All PBL exper-
iments were replicated with cells from at least three different donors.
Bead Labeling
1 mm polystyrene microspheres were obtained from Polysciences
(2.6% m/v). The beads were diluted to a stock solution of 1.3%
(m/v) in DI water with 0.1% NaN3 and sonicated for 15 min before
each use. Beads (10 ml of stock solution) were labeled by incubation
with monoclonal F(ab)’ fragments or ICAM-1 (0.1–10 mg) for 1 hr in0.2 ml of borate buffer (100 mM borate, 1 mM EDTA, 0.1% NaN3
[pH 8.5]) at a final bead concentration of 0.05% (m/v). In all cases,
we used the minimum amount of protein required to achieve selec-
tive binding of beads to cells. Control beads were labeled with poly-
clonal F(ab)’ or BSA under identical conditions. After adsorption of
the protein to the beads, the samples were diluted to 1 ml with block-
ing buffer (10 mM HEPES, 140 mM NaCl, 1 mM EDTA, 2% dextran,
1% BSA, 0.1% NaN3, 0.1 mg/mL PEG-compound [pH 7.4]) and incu-
bated for 1 hr. The samples were then sonicated for 15 min and
centrifuged at 5000 RPM for 7 min. The supernatant was aspirated
to 0.1 ml final volume, resuspended, and sonicated for 15 min imme-
diately before use. All labeled bead samples were used within 48 hr
of preparation. Selectivity of binding was confirmed at the start of
each experiment by manually counting the number of positively la-
beled cells in w20 random fields. Samples were used for tracking
experiments if the selectivity of bead binding was more than 4-fold
greater than the isotype control. Bead binding was typically 0.4%
of cells for control beads and 2% (5-fold selectivity) for ICAM-
1- (0.1 mg), 4% (10-fold) for TS1/18- (1.0 mg), 3% (6-fold) for MEM-
148- (1.0 mg), and 3% (6-fold) for HI111- (1.0 mg) labeled beads.
Single-Particle Tracking
Cells were observed on a Nikon TE2000-E microscope equipped
with DIC optics, with a 603 oil objective with an oil condenser
(NA = 1.4) (Mirchev and Golan, 2001). Images of a single bead on
individual cells were captured at 1000 FPS with a Fastcam Super
10K camera (Photron USA, Inc., San Diego, CA). Video data were
processed with Metamorph (Universal Imaging, Downington, PA)
and converted to trajectories. Trajectory data were analyzed with
mean square displacement (MSD) analysis (Saxton and Jacobson,
1997) implemented in a custom program written in Matlab (Math-
works, Inc., Natick, MA) (see Supplemental Data). Jurkat cells
were nonmotile under the conditions used for these experiments,
but some PBL showed evidence of motility. Cell motility did not af-
fect the interpretation of SPT data collected on PBL (see Figure S3).
Fluorescence Photobleaching Recovery
Jurkat cells were collected in exponential growth, washed three
times with HBSSB, and then incubated for 30 min at 37C with
HBBSB containing DMSO (0.1% v/v) or DMSO with PMA
(200 ng/mL). Cells were then labeled for 15 min with FITC-conju-
gated F(ab)’ fragments (20 mg/mL) and transferred to a 6-well plate
containing fresh HBSSB and a BSA-coated coverslip. For lipid diffu-
sion experiments, NBD-PE was added to the cell suspension
(10 mg/mL) for 15 min. The plate was centrifuged at w500 RPM for
7 min to settle cells onto the glass. The coverslip was then washed
twice with fresh HBSSB, transferred to a microslide, and sealed
with vacuum grease and Cytoseal. Samples were observed within
90 min of sealing. FPR experiments were conducted on a Meridian
Ultima workstation (Okemos, MI), with a 403 objective (NA = 1.3).
Fluorescence recovery was observed over a 50–200 s period after
the photobleach, depending on the rate of recovery. All experiments
were performed on at least two separate days, with two different
samples per experiment.
Supplemental Data
Supplemental Data include two tables, four figures, and Supplemen-
tal Experimental Procedures and can be found with this article online
at http://www.immunity.com/cgi/content/full/25/2/297/DC1/.
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